On November 25, 2020, Inspyr Therapeutics, Inc. (the "Company") entered into a conversion price adjustment agreement (the "Agreement") with Sabby Healthcare Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (collectively, "Sabby") (Filing, 8-K, Inspyr Therapeutics, NOV 25, 2020, View Source [SID1234571843]). Pursuant to the Agreement, approximately $2,383,150 in outstanding senior convertible debentures (the "Debentures") held by Sabby were amended such that their conversion prices into common stock ("Common Stock") of the Company are equal to the lesser of (i) $0.33 and (ii) 85% of the lowest volume-weighted average price during the five trading days immediately prior to the date of conversion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!